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ABSTRACT 
Objective: Patient noncompliance in taking medication is the problem in hypertension therapy. This study aims to describe the compliance to drug 
use in hypertensive patients in Bengkulu, Banjarmasin, and Yogyakarta, Indonesia. 
Methods: This study is an observational study using a questionnaire, with a total sample size of 300. Data are analyzed by using bivariate analysis 
with the chi-square method to see if there is a relationship between compliance and predetermined variables. 
Results: The study in three cities showed that there were 0 patients (0%) Low compliance and non-compliance category patients; the compliance 
category was 91%, 10%, 8%, respectively. High compliance categories were 9%, 90%, 92%. Chi-square test shows that compliance has a significant 
relationship (*P<0.05) in the three cities on the variable "treatment motivation", other variables that show a significant relationship in the city of 
Yogyakarta are "drug side effects", "role of health workers", "social support", in Bengkulu is "Therapeutic beliefs", in Banjarmasin is" Knowledge of 
therapeutic effects ". 
Conclusion: All hypertensive patients have good compliance; compliance is significantly associated in all three cities on the variable "treatment 
motivation." 
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INTRODUCTION 
Hypertension is an extraordinary global problem. It ranks third as 
the cause of decreased life expectancy and disability [1]. 
Hypertension is defined as a continuous increase from blood 
pressure to 140/90 mmHg or higher, the risk of hypertension can be 
increased gradually; gradually concomitant increase in systolic and 
diastolic blood pressure [2]. If it is not handled properly, it can cause 
complications that are more dangerous for sufferers, including an 
increased risk of stroke, kidney failure and heart failure [3-5]. The 
stroke risk is reduced if the initial systolic blood pressure (SBP) is 
more than 140 mm Hg and after receiving therapy, the SBP is 
achieved less than 140 mm Hg [6]. 
To achieve the goal of hypertension therapy, several strategies are 
needed in addition to the use of appropriate drugs, such as patient 
compliance, both compliance in seeing a doctor, compliance in 
taking medication, compliance to lifestyle and diet, and emotional 
stability [7, 8]. The pharmacist’s role to achieve the goals of this 
therapy is to provide pharmaceutical care in the use of drugs so that 
patients become more obedient in using drugs according to doctor's 
recommendations [9]. 
To be able to carry out appropriate pharmaceutical care strategies 
for hypertensive sufferers, pharmacists must know the level of 
patient compliance in using drugs so that the level of compliance 
with patient drug use must be measured in advanced. 
MATERIALS AND METHODS 
Ethical approval 
This research has received an Ethical Approval from the Research 
Ethics Committee of the Ahmad Dahlan University of Indonesia No: 
011911109 in December 2019. The research methodology used is 
observational analytic with a Cross-Sectional approach. 
Data collection 
Data collection used is a self-made questionnaire to measure the 
level of patient compliance with 5 variables (V). V-1 is the 
compliance variable using drug doses, V-2 is the compliance variable 
in the frequency of drug use, V-3 compliance variable in time of drug 
use, V-4 compliance variable in drug use interval, and V-5 
compliance variable for the duration of drug use. 
The variables affecting compliance used 11 variables including 
family support, drug side effects, treatment costs, the role of health 
workers, therapy beliefs, knowledge of the effects of therapy, drug 
information provision, motivation for treatment, affordability of 
health services, busy work status, social support.  
Data analysis 
The relationship between compliance and variables affecting 
compliance was analyzed using the chi-square, one-way, with an 
error rate of 0.05%. There was a statistically significant difference if 
*P<0.05. 
RESULTS AND DISCUSSION 
The questionnaire was tested for the validity of 150 respondents 
using the Pearson Correlation technique; the validity test shows that 
each question item has a value of r-Count greater than r- table, so it 
is concluded that all question items are valid. 
Compliance is categorized into four categories, namely: Low 
compliance, non-compliance, compliance, and very compliance. The 
results can be seen in table 1. 
Based on table 1, in general, hypertensive patients in the three cities 
shows none in non-compliance to drug use. It is indicated by a zero 
value, at the level of non-compliance and low-compliance. Overall, 
patients in three cities are categorized as compliance (100%). 
There is a slight variation in the levels of compliance and high-
compliance, in Bengkulu City, the level of compliance is higher than 
the other two cities. For Yogyakarta City, the level of high-
compliance is higher than in the other two cities. 
The results of this study are different from the research conducted 
by Osamor (2011), a study conducted in Southwest Nigeria, it is 
reported that patients are compliance to taking hypertension drugs 
only 50.7% [10], while Mahmoud (2012), reported that the level of 
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patient compliance in the city of Medina as much as 15.6% [11], 
Chusna (2014) reported the level of compliance of hypertensive 
patients at dr. Doris Sylvanus Palangkarya, Indonesia as much as 
43% [12], Rahmadani (2018) reported that the level of compliance 
of hypertensive patients at the public health center in Yogyakarta 
City, Indonesia is 59.1% [13]. 
 





Bengkulu Banjarmasin Yogyakarta Average 
% Number of patients (N) % Number of 
patients (N) 
% Number of patients (N) % 
Low-compliance 0–4.75 0 0 0 0 0 0  0 
non-compliance 4.75–9.5  0 0 0 0 0 0  0 
compliance 9.5–14.25 16 16  10 10 8 8   11.4  
High-compliance 14.25–19 84 84 90 90 92 92  88.6  
 
From the data obtained by the researcher, the main factor causing 
the decrease in compliance rate is caused by variable V-4; the 
compliance variable in the interval of drug use, with the question 
"Do you always use the drug at the same time every day?". In this 
question there were 22% of patients answered "no", it means that 
22% of patients did not take the drug at the same time every day, 
some patients took the drug in the morning, sometimes at 6 am or 7 
am or 8 am, for it is important that they drink the medicine every 
morning. The duration of taking medication from one dose to 
another has an effect on drug levels in the blood [14], hypertensive 
drugs such as amlodipine, irbesartan have a t1/2 elimination long 
enough so that the frequency of use is enough once a day [15], this 
factor causes the difference in the hours taking medicine does not 
really affect the level of the drug in the blood, unless the distance to 
taking medicine is too long, for example on the first day it is taken in 
the morning, and the next day the drug is taken at night. 
 
Table 2: Distribution of respondents according to variables affecting patient compliance 
Variabel Statement Bengkulu % Banjar-masin % Yogya-karta % Average % 
Family support S 89.8 92 40 73.9 
NS 10.2 8 60 26.1 
Side effects NSE 91.8 88 91 90.3 
SE 8.2 12 9 9.7 
Medical cost/insurance UI 88.8 85 42 71.9 
DUI 11.2 15 58 28.1 
The role of health workers high 92.9 89 83 88.3 
low 7.1 11 17 11.7 
Therapeutic beliefs beliefs 91.8 98 74 87.9 
Not beliefs 8.2 2 26 12.1 
Knowledge level of therapeutic effects high 69.4 85 80 78.1 
low 30.6 15 20 21.9 
Drug information administration DI 92.9 93 42 76.0 
NDI 7.1 7 58 24.0 
Motivation for treatment high 96.9 91 64 84.0 
low 3.1 9 36 16.0 
Affordability of health services Aff 77.6 84 68 76.5 
NA 22.4 16 32 23.5 
Busyness status busy 95.9 5 30 43.6 
not busy 4.1 95 70 56.4 
Social support. 
 
S 85.7 95 63 81.2 
NS 14.3 5 37 18.8 
Note: S: Supported; NS: Not Supported, NSE: no side effects, SE: are side effects; UI: Using insurance; DSU: Don't use insurance; DI: got drug 
information; NDI: didn't get drug information; Aff: Affordable NA: not affordable 
 
Based on table 2 it can be seen that all the variables affecting patients 
taking hypertension drugs are influential, only in Yogyakarta City, there 
are several variables including family support, medical/insurance costs, 
providing information on drugs that have a lower status effect than the 
two other cities. This difference can be because the city of Yogyakarta is a 
large city, its residents live in urban areas, residents in urban areas are 
usually more independent, have better access to information and have 
above average income [16]. 
 
Table 3: Chi-Square test results, the relationship between the levels of compliance with variables that influence it 
No Variabel  Bengkulu Banjarmasin Yogyakarta 
OR P-value OR P-value OR P-value 
1 Family support 1.321 0.665 3.500 0.182 0.368 0.261 
2 Side effects 3.554 0.120 2.000 0.343 8.600 0.023 
3 Medical cost/insurance 1.159 1.000 2.786 0.171 0.275 0.404 
4 The role of health workers 0.844 1.000 4.393 0.078 6.007 0.027 
5 therapeutic beliefs 11.970 0.003 9.889 0.191 3.182 0.200 
6 Knowledge level of therapeutic effects 1.450 0.559 8.000 0.006 2.647 0.196 
7 Drug information administration 0.800 1.000 1.556 0.533 0.918 1.000 
8 Motivation for treatment  0.137 0.004 6.000 0.044 5.192 0.040 
9 Affordability of health services  2.475 0.186 2.538 0.198 3.310 0.380 
10 Busyness status 1.756 0.516 2.389 0.416 0.485 0.236 
11 Social support. 2.400 0.236 2.389 0.416 4.908 0.009 
There was a statistically significant difference if *P<0.05 
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The results of the Chi-Square test regarding the relationship between 
compliance and variables that influence it can be seen in table 3, all 
variables, such as family support, drug side effects, treatment costs, the 
role of health workers, therapeutic beliefs, knowledge of therapeutic 
effects, providing drug information, motivation for treatment, 
affordability of health services, busyness status, and social support 
have an effect on compliance. The ones that have a statistically 
significant effect are the variables motivation for treatment. Variable 
Motivation for treatment is quite high, reaching 84% (table 2). The test 
results show a significant relationship with a study conducted by Sari 
(2019) on pulmonary TB patients showing that motivation for 
treatment has a significant relationship with compliance [17]. 
Research conducted by Varming (2015), also shows that motivation 
for treatment is very influential on compliance to medication [18]. The 
results of research conducted by Nuratiqa, N, (2020) on hypertensive 
patients also shows motivation to seek treatment is significantly 
related to compliance [19, 20]. 
The variables drug side effects, the role of health workers, social 
support, therapy beliefs, knowledge of therapeutic effects gave a 
significant difference even if only in one city. Similar conclusions 
were also obtained by researcher Nurhanani (2020) who carried out 
hypertension patients in Semarang City, namely that compliance to 
taking medication was significantly related to busy work status, 
knowledge of how to take medicine and social support [21]; 
conclusions also obtained by Rasajati researchers (2015), 
compliance to taking medication was significantly related to 
distance from the house to health services, level of knowledge about 
hypertension management, motivation treatment, and family 
support [22]. Khan (2014) also stated that there are four main 
factors that cause non-compliance to taking medication in 
hypertensive patients, namely the emergence of “drug side effects”, 
“forgetfulness”, “busyness status” and “the inconvenience of taking 
medication when outside the home” [23]. 
CONCLUSION 
In general, the research objects in three cities in Indonesia have 
good and very good levels of compliance in taking medication. 
Compliance in taking medication is significantly influenced by 
treatment motivation. 
ACKNOWLEDGMENT 
The author would like to thank those who helped this research, the 
regional governments of Bengkulu, Banjarmasin, and Yogyakarta 
City, as well as the Ahmad Dahlan University Yogyakarta Research 
Department, patients as the objects of this research and pharmacist 
colleagues who helped a lot in this report. 
FUNDING 
No competing financial interests exist. 
AUTHORS CONTRIBUTIONS  
The first author of this study made research designs, controlled data 
collection, processed data, compiled reports, and presented reports. 
The second, third, and fourth authors are responsible for data 
collection, and the fifth author is responsible for data processing. 
CONFLICT OF INTERESTS  
All authors have no conflict of interest with any party. 
REFERENCES 
1. Osamor PE, Owumi BE. Factors associated with treatment 
compliance in hypertension in southwest Nigeria. J Health 
Popul Nutr 2011;29:619-28.  
2. Goodman and Gilman's. The pharmacological basis of 
therapeutics. Thirteenth Edition. USA: McGraw-Hill Education; 
2018. 
3. Tackling G, Borhade MB. Hypertensive heart disease. In: 
StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. 
4. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in 
chronic kidney disease. Drugs 2019;79:365–79.  
5. Sinha AD, Agarwal R. Clinical pharmacology of 
antihypertensive therapy for the treatment of hypertension in 
CKD. Clin J Am Soc Nephrol 2019;14:757–64. 
6. Brunström M, Carlberg B. Effect of antihypertensive treatment 
at different blood pressure levels in patients with diabetes 
mellitus: systematic review and meta-analyses. Br Med J 
2016:352;i717.  
7. Muhlis M, Prameswari A. Kepatuhan penggunaan obat pada 
pasien hipertensi di Instalasi Rawat Jalan Salah Satu RSUD di 
wilayah Daerah Istimewa Yogyakarta. Jurnal Insan Farmasi 
Indonesia 2020;3:104-13.  
8. Gupta R, Guptha S. Strategies for initial management of 
hypertension. Indian J Med Res 2010;132:531–42. 
9. Sinuraya RK, Destiani DP, Puspitasari IM, Diantini A. 
Pengukuran tingkat kepatuhan pengobatan pasien hipertensi 
di Fasilitas Kesehatan Tingkat Pertama di Kota Bandung. 
Indones J Clin Pharm 2018;7:124-33. 
10. Dharan DR, Molly KT. Factors influencing compliance to 
therapeutic regimen among patients with hypertension. Asian J 
Pharm Clin Res 2017;10:286-9.  
11. Mahmoud MIH. Compliance with the treatment of patients with 
hypertension in almadinah almunawwarah: a community-
based study. J Taibah University Med Sci 2012;7:92-8.  
12. Chusna N, Puspitasari I, Probosuseno P. Pengaruh kepatuhan 
dan pola pengobatan terhadap hasil terapi pasien hipertensi. J 
Management Pharm Pract 2014;4:230-5. 
13. Rahmadani MA, Sari A. Kepatuhan terhadap pengobatan pada 
pasien hipertensi dengan komplikasi diabetes melitus di 
Puskesmas Yogyakarta. Media Farmasi 2018;15:1-5. 
14. DiPiro JT, Spruill WJ, Wade WE, Blouin RA, Pruemer JM. 
Concepts in clinical pharmacokinetics. 5th Ed. Ohio: American 
Society of Health-System Pharmacists; 2010. 
15. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug 
information handbook. Ohio: Lexi-Comp Inc; 2007. 
16. Jamaludin AN. Sosiologi perkotaan: memahami masyarakat 
kota dan problematikanya. Bandung: Penerbit CV Pustaka 
Setia; 2015. 
17. Sari LT. Hubungan motivasi kesembuhan dengan kepatuhan 
minum obat pada penderita TB paru dewasa. JuKe 2019;3:1-8. 
18. Hasan M. Hubungan motivasi kesembuhan dengan kepatuhan 
minum obat penderita tuberkulosis paru di puskesmas jambe 
kabupaten tangerang. J Penelitian Pengabdian Masy 2019;2:1-10. 
19. Nuratiqa N, Risnah R, Hafid MA, Paharani A, Irwan M. Faktor 
yang berhubungan dengan kepatuhan minum obat anti 
hipertensi. BIMIKI 2020;8:1-10. 
20. Varming AR, Hansen UM, Andresdottir G, Husted GR, Willaing I. 
Empowerment, motivation, and medical adherence (EMMA): 
the feasibility of a program for patient-centered consultations 
to support medication adherence and blood glucose control in 
adults with type 2 diabetes. Patient Prefer Adheren 
2015;9:1243–53.  
21. Nurhanani R, Susanto HS, Udiyono A. Hubungan faktor 
pengetahuan dengan tingkat kepatuhan minum obat 
antihipertensi (Studi pada pasien hipertensi essential di 
wilayah kerja Puskesmas Bandarharjo Kota Semarang). J Kes 
Masy 2020;8:114-21.  
22. Rasajati Q, Raharjo B, Ningrum DN. Faktor-faktor yang 
berhubungan dengan kepatuhan pengobatan pada penderita 
hipertensi di wilayah kerja Puskesmas Kedungmundu Kota 
Semarang. Unnes J Pub Health 2015;4:16-23. 
23. Khan MU, Shah S, Hameed T. Barriers to and determinants of 
medication adherence among hypertensive patients attended 
National Health Service Hospital, Sunderland. J Pharm Bioallied 
Sci 2014;6:104-8. 
 
